Abstract P1038: Blood Metabolomic Signatures of Incident Coronary Heart Disease in Racially and Ethnically Diverse Populations

K Kai Luo T Taryn Alkis (The University of Texas Health Science Center at Houston, Houston, Texas, United States) E Eun Hye Moon (UTHealth at Houston, Houston, Texas, United States) C Christie Ballantyne (BAYLOR COLLEGE MEDICINE, Houston, Texas, United States) E Eric Boerwinkle C Clary Clish R Robert Gerszten M Megan Grove (UTHealth, Houston, Texas, United States) L Lifang Hou S Scott Hutton (Metabolon, Inc, Morrisville, North Carolina, United States) R Robert Kaplan R Rozenn Lemaitre (Cardiovascular Health Research Unit, Department of Medicine University of Washington, Seattle, Washington, United States) D Donald Lloyd-Jones (Framingham Center for Population and Prevention Science, Framingham, MA) M Matthew Nayor K Kari North (UNIV OF TX HEALTH SCI CTR HOUSTON, Houston, Texas, United States) B Bruce Psaty (University of Washington, Seattle, WA, USA.) L Laura Raffield S Stephen Rich J Jerome Rotter (The Lundquist Institute, Torrance, California, United States) U Usman Tahir (Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States) T Tao Wang K Kari Wong V Vanessa Xanthakis Q Qibin Qi B Bing Yu (College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry)

Abstract

Background: Metabolic perturbation has been characterized in coronary heart disease (CHD), yet the comprehensive metabolic fingerprint of incident CHD and potential racial/ethnical differences remain unclear. Hypothesis: Circulating metabolite alterations are associated with CHD risk, but associations vary across race/ethnicity. Methods: We included 22,566 CHD-free individuals of multi-ethnic groups from 7 studies in the Trans-Omics for Precision Medicine Program ( Fig.a ). Associations between metabolites (1245 named metabolites) and incident CHD were assessed by study/race-specific Cox proportional hazards regression. Results were pooled via random-effect meta-analyses. Results: Over an average of 7.5~17.0 yrs of follow-up 1124 incident CHD cases were recorded. We found that 280 metabolites were associated with incident CHD after adjusting for sociodemographic, behavioral factors, medications use, physical activity, and diet (FDR < 0.05), with over 64% were independent of other major cardiometabolic traits ( Fig.b ). Over 90% of these metabolites showed positive associations, with strongest associations in metabolites of glycerolipids, phosphatidylethanolamine, fatty acids, lactoyl amino acid, histidine, aromatic amino acids, and branched amino acids ( Fig.b ). Race-specific analyses identified 70 metabolites presenting significant race/ethnicity differences (FDR<0.05) in associations with CHD, with 34 being race/ethnicity specific metabolites that were not found in all participants (16 in Blacks, 11 in Whites and 7 in Hispanics; Fig.c-e ). For example, guanidinosuccinate, a known uremic toxin, was associated with increased risk of CHD only in US Hispanics, reinforcing the chronic kidney disease (CKD)-cardiovascular diseases continuum, especially for populations at high risk of CKD. Conclusion: Our study characterized the most comprehensive metabolic signatures of incident CHD and revealed substantial racial differences, further emphasizing the need of multi-ethnic resources to uncover metabolic perturbation underlying CHD.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue Suppl_1
Published March 11, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (25)

K

Kai Luo

T

Taryn Alkis

The University of Texas Health Science Center at Houston, Houston, Texas, United States

E

Eun Hye Moon

UTHealth at Houston, Houston, Texas, United States

C

Christie Ballantyne

BAYLOR COLLEGE MEDICINE, Houston, Texas, United States

E

Eric Boerwinkle

C

Clary Clish

R

Robert Gerszten

M

Megan Grove

UTHealth, Houston, Texas, United States

L

Lifang Hou

S

Scott Hutton

Metabolon, Inc, Morrisville, North Carolina, United States

R

Robert Kaplan

R

Rozenn Lemaitre

Cardiovascular Health Research Unit, Department of Medicine University of Washington, Seattle, Washington, United States

D

Donald Lloyd-Jones

Framingham Center for Population and Prevention Science, Framingham, MA

M

Matthew Nayor

K

Kari North

UNIV OF TX HEALTH SCI CTR HOUSTON, Houston, Texas, United States

B

Bruce Psaty

University of Washington, Seattle, WA, USA.

L

Laura Raffield

S

Stephen Rich

J

Jerome Rotter

The Lundquist Institute, Torrance, California, United States

U

Usman Tahir

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

T

Tao Wang

K

Kari Wong

V

Vanessa Xanthakis

Q

Qibin Qi

B

Bing Yu

College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry